Seattle Children's
This page includes a searchable index of all resources created by Seattle Children’s Hospital and University of Washington. If you would like to add a resource to this index, please contact us.
Improving Palivizumab Administration to High-Risk Infants with Heart Disease via a Communication-Based Quality Improvement Initiative
2025
· Yale University,
· Yale New Haven Health System
This article describes a project to improve the administration of palivizumab, a medication for high-risk infants with heart disease. A team at Yale University worked …
Ask aRCie
Challenges in Maximizing Impacts of Preventive Strategies Against Respiratory Syncytial Virus (RSV) Disease in Young Children
2022
· Yale University
This article discusses the challenges and advancements in preventive strategies against Respiratory Syncytial Virus (RSV) disease in young children. RSV is a common cause of …
Monoclonal Antibodies for Prophylaxis and Treatment of Respiratory Viral Infections
This article discusses the use of monoclonal antibodies (mAbs) to prevent and treat respiratory viral infections, especially in people with weak immune systems. It describes …
Respiratory Syncytial Virus-An Update for Prenatal and Primary Health Providers
2023
· University of Washington,
· State University of New York - Upstate Medical University,
· Seattle Children's Hospital
This article provides an update on respiratory syncytial virus (RSV) for prenatal and primary health providers. It emphasizes the lack of data on RSV infection …
Cost-Effectiveness Analysis of Nirsevimab and RSVpreF Vaccine Prevention Strategies for Respiratory Syncytial Virus Disease in Infants: A Canadian Immunisation Research Network (CIRN) Study
2023
· York University,
· Yale University,
· Dalhousie University
This study looks at the cost-effectiveness of two strategies to prevent RSV disease in infants in Canada. It describes using nirsevimab, a long-acting antibody, for …
Cost-Effectiveness Analysis of Nirsevimab and Maternal Rsvpref Vaccine Strategies for Prevention of Respiratory Syncytial Virus Disease Among Infants in Canada: A Simulation Study
2023
· Yale University,
· York University,
· Dalhousie University
This study in Canada assessed cost-effectiveness of nirsevimab and RSVpreF for preventing RSV in infants. Modeling different interventions showed immunizing the birth cohort with nirsevimab …
Game Over for RSV?
2023
· Yale University
This letter comments on a study by D. Wilkins and colleagues and concludes that passive immunization with nirsevimab protects infants from severe respiratory syncytial virus …
Early Experiences With Nirsevimab: Perspectives From Newborn Hospitalists
2024
· Yale School of Medicine,
· Stanford University,
· Seattle Children's Hospital,
· The University of Chicago Medicine,
· Nationwide Children's Hospital,
· Yale University
This article discusses the implementation of newly developed nirsevimab into clinical practice. Approved in July 2023, it is costly and has supply issues. Hospitals struggle …
Real-World Effectiveness of Nirsevimab Against Respiratory Syncytial Virus: A Test-Negative Case-Control Study
2024
· Yale School of Medicine,
· Yale University
This article describes a study that evaluated the effectiveness of nirsevimab in preventing RSV infections in infants. It included 3,090 infants and found that nirsevimab …
Factors Associated With Nirsevimab Uptake in Healthy Newborns
2024
· Yale School of Medicine,
· Yale University
This research brief discusses a study that looks at factors affecting the use of nirsevimab, a new antibody for RSV, in newborns. It explains how …